PT  - JOURNAL ARTICLE
AU  - Marion A J van Rossum
AU  - Renée M van Soesbergen
AU  - Maarten Boers
AU  - Aeilko H Zwinderman
AU  - Theo J W Fiselier
AU  - Marcel J A M Franssen
AU  - Rebecca ten Cate
AU  - Lisette W A van Suijlekom-Smit
AU  - Nico M Wulffraat
AU  - Wietse Kuis
AU  - Wilma H J van Luijk
AU  - Johanna C M Oostveen
AU  - Ben A C Dijkmans
AU  - on behalf of the Dutch Juvenile Idiopathic Arthritis Study group
TI  - Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment
AID  - 10.1136/ard.2006.064717
DP  - 2007 Nov 01
TA  - Annals of the Rheumatic Diseases
PG  - 1518--1524
VI  - 66
IP  - 11
4099  - http://ard.bmj.com/content/66/11/1518.short
4100  - http://ard.bmj.com/content/66/11/1518.full
SO  - Ann Rheum Dis2007 Nov 01; 66
AB  - Objectives: A previous 24-week randomised trial demonstrated that sulfasalazine (SSZ) treatment was superior to placebo (PLAC) in suppressing disease activity in patients with oligo- and polyarticular onset juvenile idiopathic arthritis (JIA). The current study determines the long-term outcome of the trial participants and evaluates whether the benefits of SSZ allocation are sustained over time.Methods: Between 2001 and 2003, 32 SSZ and 29 PLAC patients (90% of all patients) were prospectively examined clinically and by chart review, median 9 years (range 7 to 10) after trial inclusion. In the follow-up assessment, variables of the American College of Rheumatology Pediatric 30 (ACR Pedi 30) criteria were collected. The assessor was blinded to trial treatment allocation.Results: After the trial, patients had been routinely followed in rheumatology referral centres, and treated at the discretion of the attending physician. Almost all patients continued or started disease-modifying antirheumatic drugs (DMARDs) (SSZ 91%, PLAC 93%; SSZ treatment in about 80%). DMARD treatment appeared less intensive in the SSZ group as evidenced by a significantly shorter duration of SSZ use (median 2.5 vs 5.2 years; p = 0.02) and a trend towards less use of methotrexate and other DMARDs. More than one-third of the patients reported long periods of non-compliance with DMARD treatment in both groups.At follow-up, 74% of the patients had active joints, and 30% showed active polyarthritis. Almost all outcome scores were better for SSZ compared with PLAC patients. Differences (often exceeding 50%) were significant for the number of active joints, patients’ overall well-being, number of patients with episodes of clinical remission off medication (CROM) and duration of these episodes, patients in CROM and ACR Pedi 30 response at follow-up. Additional exploratory analyses performed to detect potential confounders related to patient characteristics or follow-up treatment showed that DMARD treatment compliance was positively correlated with an ACR Pedi 30 response (odds ratio 3.8, 95% confidence interval (CI) 1.1 to 13.4; p = 0.03). Adjusted for compliance, an SSZ patient was 4.2 times as likely as a PLAC patient to be an ACR Pedi 30 responder at follow-up (95% CI 1.3 to 14.3; p = 0.02).Conclusions: This follow-up study shows that effective suppression of disease activity by SSZ treatment early in active disease in JIA patients has beneficial effects that persist for many years. Given these results, compliance with DMARD treatment deserves serious attention.